People · Operator
Named in public records as an officer, director or promoter · active 2009–2018 · Biotechnology, Other Health Care, Other, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Celularity Inc. | — | Biotechnology | Series C | $117.7M | $3.2B | 2017 |
| Provista Diagnostics Inc. | — | Biotechnology | Series A | $41.6M | $79.7M | 2012 |
| Bionik Laboratories Corp. | — | Other Health Care | Series B | $41.3M | $27.7M | 2015 |
| Rocket Racing Inc | — | Other | Series A | $6.5M | $84.1M | 2009 |
| Primus Therapeutics Inc. | — | Pharmaceuticals | Pre-Seed | $800K | $14.2M | 2010 |
Robert Hariri at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert Hariri on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| PETER DIAMANDIS | 1 | 10 |
| John Sculley | 1 | 6 |
| Peter H. Diamandis | 1 | 5 |
| Robert J Hariri | 1 | 5 |
| Henry Ji | 1 | 5 |
| Timothy Smith | 1 | 5 |
| Thomas Mendell | 1 | 5 |
| CARLOS RAMIREZ | 1 | 4 |
| Peter Bloch | 1 | 4 |
| Andrew Pecora | 1 | 4 |
| Michael D'Angelo | 1 | 4 |
| Tim Smith | 1 | 4 |
| Timothy McCarthy | 1 | 3 |
| Andrew Von Eschenbach | 1 | 3 |
| Thomas G. Mendell | 1 | 3 |
| MARK LIEBERMAN | 1 | 3 |
| David Reese | 1 | 3 |
| Jaisim Shah | 1 | 3 |
| Michal Prywata | 1 | 2 |
| Yoji Nimura | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.